ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1497

Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies

Alan Kivitz1, Joel Kremer 2, Clarence Legerton 3, Jacqueline Palmer 4, Xiangyi Meng 4, Luminita Pricop 4 and Atul Singhal 5, 1Altoona Center for Clinical Research, Duncansville, PA, 2Albany Medical College, Albany, NY, 3Low Country Rheumatology/Articularis Healthcare, North Charleston, SC, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5Southwest Rheumatology, Dallas, TX

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Secukinumab (SEC), a selective inhibitor of interleukin 17A, demonstrated rapid, significant, and sustained improvement in the signs and symptoms of PsA, with a favorable safety profile, in the phase 3 FUTURE studies (FUTURE 1–5).1-5 These studies were conducted in several countries worldwide, including the United States. We evaluated SEC treatment in the US patient (pt) subpopulation in these studies and report pooled efficacy findings for SEC vs placebo (PBO).

Methods: Data from US pts enrolled in FUTURE 2 (NCT01752634), 3 (NCT01989468), 4 (NCT02294227), and 5 (NCT02404350) were pooled and included in this hypothesis-generating analysis. These studies used approved SEC doses, with pts receiving SEC 300 or 150 mg with subcutaneous loading dose (LD), 150 mg without LD, or PBO. FUTURE 1 (NCT01392326) was excluded because pts received an intravenous LD, which is not approved for treating PsA. Assessments included ACR20/50/70 and additional disease activity and quality of life (QOL) outcome measures at week 16. Responses were calculated using nonresponder imputation. No adjustment was made for multiple comparisons.

Results: Of 279 pts included in this pooled analysis, 72 were randomized to SEC 300 mg with LD, 83 to SEC 150 mg with LD, 34 to SEC 150 mg without LD, and 90 to PBO. Baseline characteristics were similar across treatment groups (Table 1). Most pts had a BMI of ≥ 30 kg/m2 and had been previously treated with tumor necrosis factor inhibitors (TNFis). At week 16, ACR20/50/70 response rates were numerically higher with all doses of SEC than with PBO; responses were seen as early as week 4 (Figure 1). SEC also improved other disease manifestations, including joint, skin, and nail disease, and various QOL measures; resolution of enthesitis and dactylitis was observed in approximately 50% of pts (Table 2). Overall, SEC 300 mg led to higher response rates than SEC 150-mg doses. SEC 150 mg with LD was associated with better response rates than that without LD.

Conclusion: SEC was efficacious in US pts with PsA, leading to rapid improvements in clinical endpoints and QOL. In general, US pts treated with SEC 300 mg achieved the highest response rates, including ACR50/70 response. SEC 150 mg also led to clinical benefits, with an LD regimen associated with higher response rates. Although US pts had high BMIs and a large proportion had been treated with ≥ 2 TNFis, response rates in these pts were similar to those seen in the overall pooled pt population.6,7 Our findings are consistent with those from previous studies and show that SEC is an effective treatment for pts with PsA.

References

  1. Mease PJ, et al. RMD Open. 2018;4:e000723.
  2. McInnes IB, et al. Lancet. 2015;386:1137-1146.
  3. Nash P, et al. Arthritis Res Ther. 2018;20:47.
  4. Kivitz A, et al. J Clin Rheumatol. 2018;24(suppl 3).
  5. Mease PJ, et al. Ann Rheum Dis. 2018;77:890-897.
  6. Gottlieb AB, et al. Arthritis Rheumatol. 2018;70(suppl 10) [abstract 2564].
  7. Orbai AM, et al. Arthritis Rheumatol. 2018;70(suppl 10) [abstract 2562].


Disclosure: A. Kivitz, AbbVie, 5, Amgen, 1, 4, 5, Boehringer Ingeleheim, 5, Boehringer Ingelheim, 5, Celgene, 8, Flexion, 5, 8, Flexion Therapeutics, 8, Genzyme, 5, 8, Gilead, 1, 4, 5, Gilead Sciences, Inc., 4, Horizon, 8, Janssen, 5, Janssen Research & Development, LLC, 2, Merck, 8, Novartis, 1, 4, 8, Pfizer, 1, 4, 5, 8, Regeneron, 1, 5, 8, Sanofi, 1, 4, 5, 8, Sun Pharma, 5, SUN Pharma Advanced Research, 5, UCB, 5; J. Kremer, AbbVie, 2, 5, Amgen, 5, Bristol-Myers Squibb, 2, 5, Corrona, 1, Genentech, 2, 5, Gilead, 5, Lilly, 2, 5, Novartis, 2, Pfizer, 2, 5, Regeneron, 5, Sanofi, 5; C. Legerton, AbbVie, 2, Amgen, 2, Bristol-Myers Squibb, 2, Novartis, 2, Pfizer, 2, Lilly, 2, UCB, 2, GSK, 2, GSK/HGS, 2, Gilead, 2, R-Pharm, 2, INFLARx, 2, Regeneron, 2, Corrona, 2; J. Palmer, Novartis, 3, 4; X. Meng, Novartis, 3, 4; L. Pricop, Noavrtis, 1, 3, Novartis, 1, 3, 4; A. Singhal, AbbVie, 2, 8, Amgen, 2, AstraZeneca, 2, Bristol-Myers Squibb, 2, Fujifilm, 2, Gilead, 2, Janssen, 2, Lilly, 2, Mallinckrodt, 2, MedImmune, 2, Nichi-Iko, 2, Novartis, 2, Pfizer, 2, Regeneron, 2, Roche, 2, Sanofi, 2, UCB, 2.

To cite this abstract in AMA style:

Kivitz A, Kremer J, Legerton C, Palmer J, Meng X, Pricop L, Singhal A. Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-secukinumab-in-a-us-patient-population-with-psoriatic-arthritis-a-subgroup-analysis-of-the-phase-3-future-studies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-secukinumab-in-a-us-patient-population-with-psoriatic-arthritis-a-subgroup-analysis-of-the-phase-3-future-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology